As migration of pro-inflammatory macrophages into adipose tissue represents the initial step in obesity-induced inflammation and insulin resistance, our data suggest that inhibiting macrophage chemotaxis with Kv1.3 blockers could provide therapeutic benefits in MetS females without inhibiting other innate immune functions. Here, KCNA3 is linked to metabolic syndrome.